Liberia has commenced the first large-scale trials of an experimental Ebola vaccine.
Scientists aim to immunize around 30,000 volunteers and health care workers in the country starting Monday, the BBC reports. The trial will involve injecting each of them with a tiny amount of chimpanzee cold virus that carries safe genetic material of Ebola, tricking the human body into producing an immune response.
The medicine has been hidden in a secret location in the country since it arrived one week ago.
British pharmaceutical and healthcare company GlaxoSmithKline developed the vaccine alongside the U.S. National Institutes of Health; should the trial be successful, it would be the first preventative vaccine against the killer virus.
More than 8,500 people have died during the current Ebola outbreak, with 3,600 succumbing to the disease in Liberia alone. The number of new Ebola cases is in steady decline, however.
[BBC]
More Must-Reads from TIME
- Introducing the 2024 TIME100 Next
- The Reinvention of J.D. Vance
- How to Survive Election Season Without Losing Your Mind
- Welcome to the Golden Age of Scams
- Did the Pandemic Break Our Brains?
- The Many Lives of Jack Antonoff
- 33 True Crime Documentaries That Shaped the Genre
- Why Gut Health Issues Are More Common in Women
Write to Helen Regan at helen.regan@timeasia.com